QRX's strategy is that any dose of Moxduo contains respectively less oxycodone or morphine than the equivalent dose of either morphine or oxycodone.
I believe the FDA are already well aware of the USA oxycodone problem and have not brought this question to a notice of objection as far as QRX's application for approval of Moxduo.
On the assumption that it must be better if overall there is physically less total quantity of drugs for any given dose the balance must tilt slightly favourably towards Moxduo.
QRX Price at posting:
72.5¢ Sentiment: Buy Disclosure: Held
